公开(公告)号：EP3690050A1

公开(公告)日：2020-08-05

申请号：EP18860741.0

申请日：2018-09-27

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： TERANISHI, Yuri ,  KATO, Kazuki ,  KOGA, Hikaru ,  IGAWA, Tomoyuki ,  YAMAGUCHI, Kazuki ,  SOEDA, Tetsuhiro

IPC分类号： C12N15/13 ,  A61K39/395 ,  A61P7/04 ,  C07K16/36 ,  C07K16/46 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08

摘要： Bispecific antibodies whose FIX activation-inhibiting activity is not elevated and whose FVIII cofactor function-substituting activity is elevated have been successfully discovered.

公开(公告)号：EP3827024A1

公开(公告)日：2021-06-02

申请号：EP19840512.8

申请日：2019-07-22

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： TERANISHI, Yuri ,  IGAWA, Tomoyuki ,  SAVORY, Nasa ,  KATO, Kazuki ,  SUZUKI, Takashi ,  SHIMIZU, Shun ,  ISHII, Shinya ,  SAKA, Koichiro ,  HO, Wei Shiong Adrian

IPC分类号： C07K16/46 ,  A61K39/395 ,  A61K47/68 ,  C07K16/28 ,  C12N15/13 ,  C12P21/08

公开(公告)号：EP3812399A1

公开(公告)日：2021-04-28

申请号：EP19822018.8

申请日：2019-06-20

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： SAKASHITA, Takuya ,  SAVORY, Nasa ,  KATO, Kazuki ,  NARUSHIMA, Yuta ,  MURAKAMI, Ryuichi ,  IGAWA, Tomoyuki

IPC分类号： C07K16/46 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30

摘要： In one embodiment, a multispecific antigen-binding molecule that recognizes an antigen on an antigen-presenting cell and an antigen on a target cell, which is capable of crosslinking the antigen-presenting cell and the target cell, is provided.

公开(公告)号：EP3805400A1

公开(公告)日：2021-04-14

申请号：EP19814965.0

申请日：2019-06-03

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： TERANISHI, Yuri ,  SAVORY, Nasa ,  KATO, Kazuki ,  SUZUKI, Takashi ,  HIRONIWA, Naoka

IPC分类号： C12P21/08 ,  C07K16/00 ,  C07K16/28 ,  C12N15/09 ,  C12N15/10

摘要： In a non-limiting embodiment, the present invention relates to antigen-binding molecules containing an altered TRIM21-binding domain and having an altered cytosolic half-life; pharmaceutical compositions containing such an antigen-binding molecule; methods for using such an antigen-binding molecule; methods for increasing or decreasing the cytosolic half-life of an antigen-binding molecule containing a TRIM21-binding domain; and methods for producing an antigen-binding molecule containing an altered TRIM21-binding domain and having an increased or decreased cytosolic half-life. The present invention also relates to substitutions at specific positions in a TRIM21-binding domain that increase or decrease the cytosolic half-life of an antigen-binding molecule containing a TRIM21-binding domain.

公开(公告)号：EP3492496A1

公开(公告)日：2019-06-05

申请号：EP17834452.9

申请日：2017-07-27

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： IGAWA, Tomoyuki ,  TERANISHI, Yuri ,  KATO, Kazuki ,  KOGA, Hikaru

IPC分类号： C07K16/46 ,  C12P21/08 ,  C12N15/09

摘要： The present invention provides light chain amino acid substitutions that improve the FVIII cofactor function-substituting activity of ACE910 (Emicizumab), novel light chains showing FVIII cofactor function-substituting activity, and heavy chain amino acid substitutions that improve the FVIII cofactor function-substituting activity of novel light chain-containing bispecific antibodies.